It moves to the damage and helps cells survive what should kill them.
Por décadas, a proteína MYC foi conhecida como um acelerador do crescimento tumoral — mas pesquisadores da Oregon Health & Science University revelaram que ela também atua como uma guardiã silenciosa, reparando o DNA danificado pela quimioterapia e permitindo que células cancerosas sobrevivam ao que deveria destruí-las. Essa descoberta lança nova luz sobre por que alguns dos cânceres mais agressivos, como o pancreático, resistem aos tratamentos padrão e condena pacientes a prognósticos sombrios. No horizonte, um composto experimental chamado OMO-103 representa a esperança de que essa armadura molecular possa, finalmente, ser desarmada.
- A quimioterapia e a radioterapia funcionam destruindo o DNA tumoral — mas a proteína MYC age como um encarregado de obras, recrutando proteínas de reparo antes que o dano possa matar a célula.
- Em cânceres pancreáticos, onde a atividade do MYC é especialmente intensa, essa capacidade de autorreparo está diretamente ligada a piores desfechos para os pacientes.
- Durante anos, o MYC foi considerado um alvo intratável para medicamentos, pois bloqueá-lo de forma segura parecia impossível sem prejudicar células saudáveis.
- A identificação de sua função específica no reparo do DNA abre uma brecha: se for possível bloquear apenas esse papel, os tumores voltariam a ser vulneráveis aos tratamentos.
- O composto OMO-103 está sendo testado em ensaio clínico com pacientes de câncer pancreático avançado, com biópsias antes e depois do tratamento para medir o efeito diretamente nos tumores.
Por décadas, cientistas souberam que a proteína MYC impulsiona o crescimento do câncer, agindo como um interruptor que ordena aos tumores que se multipliquem. Mas pesquisadores da Oregon Health & Science University, liderados por Rosalie Sears e Gabriel Cohn, descobriram uma segunda função oculta: quando a quimioterapia ou a radiação danifica o DNA tumoral, uma versão modificada do MYC abandona o núcleo celular e corre até os pontos de dano, recrutando proteínas de reparo para reconstruir o que foi destruído.
Essa descoberta tem implicações diretas e graves. Os tratamentos oncológicos mais comuns funcionam justamente por sobrecarregar as células tumorais com danos irreparáveis. Se o MYC permite que essas células se recuperem antes de morrer, o tratamento falha — e o paciente paga o preço. Em cânceres pancreáticos, onde o MYC opera em alta intensidade, os dados de pacientes confirmam o padrão: maior atividade do MYC corresponde a maior capacidade de reparo e a piores prognósticos.
Por muito tempo, o MYC foi considerado um alvo impossível para medicamentos, dada a dificuldade de bloqueá-lo sem afetar células saudáveis. Mas sua função específica no reparo do DNA sugere uma vulnerabilidade explorável. Os cientistas da OHSU já estão testando essa hipótese com o composto experimental OMO-103 em um ensaio clínico com pacientes de câncer pancreático avançado. Biópsias coletadas antes e depois do uso do medicamento permitem observar, em tempo real, como bloquear o MYC transforma os tumores. Se funcionar, o tratamento dos cânceres mais dependentes dessa proteína pode mudar de forma significativa.
For decades, scientists have known that a protein called MYC drives cancer growth. It sits inside the cell nucleus, flipping switches that tell tumors to multiply and consume energy. But researchers at Oregon Health & Science University have now uncovered a second, hidden job that MYC performs—one that may explain why some cancers laugh off the very treatments designed to kill them.
When chemotherapy or radiation tears through tumor DNA, a modified version of MYC abandons the nucleus and rushes to the damage sites. There, it acts like a construction foreman, gathering the proteins needed to stitch the broken DNA back together. This discovery, led by senior researcher Rosalie Sears and first author Gabriel Cohn, reveals a mechanism that has been operating in plain sight but was never fully understood until now.
The implications are stark. Most cancer treatments work by overwhelming tumor cells with DNA damage so severe that the cells cannot survive it. Chemotherapy and radiation are, in essence, weapons that rely on breaking things faster than they can be fixed. But if a cancer cell is exceptionally good at repairing that damage—if it can patch itself up before the treatment has time to kill it—the cell lives on. It grows. It spreads. The patient's prognosis darkens.
Cohn explained the stakes in particularly aggressive cancers like pancreatic tumors, where MYC activity runs especially high. These cells endure enormous DNA stress from their own frantic growth and from the treatments meant to stop them. Yet they survive anyway. The new research suggests MYC is the reason: it actively promotes DNA repair, allowing tumor cells to weather conditions that should be lethal. When researchers examined patient-derived pancreatic cancer cells and tumor data, they found a clear pattern. Cancers with high MYC activity also showed heightened DNA repair capacity and were linked to worse outcomes for patients.
For years, MYC was considered an impossible target for drug development. Its structure makes it difficult to bind medications to it safely without harming healthy cells. But this newly identified role in DNA repair offers a potential opening. If researchers could block MYC's repair function specifically—without disrupting all of its other roles in normal cells—they might render cancer cells vulnerable again to treatment.
OHSU scientists are already testing this theory. They have developed an experimental compound called OMO-103 and are running a clinical trial with patients who have advanced pancreatic cancer. In this short-term "window of opportunity" study, patients receive biopsies before and after taking the drug, allowing researchers to observe directly how blocking MYC changes tumors in living people. The work represents a shift in how scientists think about one of cancer's most fundamental drivers—not as an untouchable force, but as a protein with exploitable vulnerabilities. If OMO-103 works, it could transform treatment for the cancers most dependent on MYC's protective embrace.
Citas Notables
MYC not only helps cancer cells grow, but also helps them survive some of the treatments created to eliminate them.— Rosalie Sears, Ph.D., OHSU
If we can interfere with MYC's role in DNA repair without disrupting all its functions in healthy cells, we could make cancer cells more vulnerable to treatment.— Rosalie Sears, Ph.D., OHSU
La Conversación del Hearth Otra perspectiva de la historia
So MYC was already known to be important in cancer. What made this discovery feel new?
The difference is between knowing a protein exists and understanding what it actually does. MYC was famous for turning on growth genes inside the nucleus. But this research found it doing something completely different—physically moving to broken DNA and fixing it. That's a role no one had fully grasped before.
Why does that matter for treatment?
Because most chemotherapy works by breaking DNA so badly that cancer cells die. But if those cells can repair the damage quickly, they survive the treatment. MYC appears to be the repair crew. Block it, and the cancer becomes defenseless again.
Is this only a problem in pancreatic cancer?
Pancreatic cancer is where it's most dramatic—the tumors there have extremely high MYC activity and terrible survival rates. But MYC is one of the two most important cancer-driving proteins across all human cancers, so this mechanism likely matters in many types.
Why couldn't they just target MYC before?
Because MYC's structure makes it hard to attach drugs to without damaging healthy cells. But now that they know it has this specific repair function, they can try to block just that piece of what it does, leaving other functions intact.
What does OMO-103 actually do?
It's designed to interfere with MYC's ability to recruit repair proteins to damaged DNA. The clinical trial is watching whether it works in real patients—whether blocking that one function makes their tumors more vulnerable to standard chemotherapy.
How soon might this help patients?
They're in early clinical trials now. If OMO-103 shows promise, it would still need years of testing before it could become standard treatment. But for patients with MYC-driven cancers who currently have few options, even the possibility of a new approach is significant.